Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Microbial efflux systems and inhibitors: approaches to drug discovery and the challenge of clinical implementation.

Kourtesi C, Ball AR, Huang YY, Jachak SM, Vera DM, Khondkar P, Gibbons S, Hamblin MR, Tegos GP.

Open Microbiol J. 2013;7:34-52. doi: 10.2174/1874285801307010034. Epub 2013 Mar 22.

2.

Microbial efflux pump inhibition: tactics and strategies.

Tegos GP, Haynes M, Strouse JJ, Khan MM, Bologa CG, Oprea TI, Sklar LA.

Curr Pharm Des. 2011;17(13):1291-302. Review.

3.

Strategies to potentiate antimicrobial photoinactivation by overcoming resistant phenotypes.

Vera DM, Haynes MH, Ball AR, Dai T, Astrakas C, Kelso MJ, Hamblin MR, Tegos GP.

Photochem Photobiol. 2012 May-Jun;88(3):499-511. doi: 10.1111/j.1751-1097.2012.01087.x. Epub 2012 Feb 13. Review.

4.

Understanding efflux in Gram-negative bacteria: opportunities for drug discovery.

Schweizer HP.

Expert Opin Drug Discov. 2012 Jul;7(7):633-42. doi: 10.1517/17460441.2012.688949. Epub 2012 May 19. Review.

PMID:
22607346
5.

Antimicrobial and efflux pump inhibitory activity of caffeoylquinic acids from Artemisia absinthium against gram-positive pathogenic bacteria.

Fiamegos YC, Kastritis PL, Exarchou V, Han H, Bonvin AM, Vervoort J, Lewis K, Hamblin MR, Tegos GP.

PLoS One. 2011 Apr 4;6(4):e18127. doi: 10.1371/journal.pone.0018127.

6.

Small Molecule Efflux Pump Inhibitors in Mycobacterium tuberculosis: a Rational Drug Design Perspective.

Kapp E, Malan SF, Sampson SL.

Mini Rev Med Chem. 2017 May 9. doi: 10.2174/1389557517666170510105506. [Epub ahead of print]

PMID:
28494730
7.

Concepts and principles of photodynamic therapy as an alternative antifungal discovery platform.

Dai T, Fuchs BB, Coleman JJ, Prates RA, Astrakas C, St Denis TG, Ribeiro MS, Mylonakis E, Hamblin MR, Tegos GP.

Front Microbiol. 2012 Apr 10;3:120. doi: 10.3389/fmicb.2012.00120. eCollection 2012.

8.

[The role of cell wall organization and active efflux pump systems in multidrug resistance of bacteria].

Hasdemir U.

Mikrobiyol Bul. 2007 Apr;41(2):309-27. Review. Turkish.

PMID:
17682720
9.
10.

Bacterial efflux pump inhibitors from natural sources.

Stavri M, Piddock LJ, Gibbons S.

J Antimicrob Chemother. 2007 Jun;59(6):1247-60. Epub 2006 Dec 4. Review.

PMID:
17145734
11.

Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy.

Lomovskaya O, Warren MS, Lee A, Galazzo J, Fronko R, Lee M, Blais J, Cho D, Chamberland S, Renau T, Leger R, Hecker S, Watkins W, Hoshino K, Ishida H, Lee VJ.

Antimicrob Agents Chemother. 2001 Jan;45(1):105-16.

12.

Bacterial efflux pumps involved in multidrug resistance and their inhibitors: rejuvinating the antimicrobial chemotherapy.

Bhardwaj AK, Mohanty P.

Recent Pat Antiinfect Drug Discov. 2012 Apr;7(1):73-89. Review.

PMID:
22353004
13.

Development of efflux pump inhibitors in antituberculosis therapy.

Song L, Wu X.

Int J Antimicrob Agents. 2016 Jun;47(6):421-9. doi: 10.1016/j.ijantimicag.2016.04.007. Epub 2016 May 10. Review.

PMID:
27211826
14.

Effect of efflux pump inhibitors on bile resistance and in vivo colonization of Campylobacter jejuni.

Lin J, Martinez A.

J Antimicrob Chemother. 2006 Nov;58(5):966-72. Epub 2006 Sep 7.

PMID:
16963459
15.

Dithiazole thione derivative as competitive NorA efflux pump inhibitor to curtail multi drug resistant clinical isolate of MRSA in a zebrafish infection model.

Lowrence RC, Raman T, Makala HV, Ulaganathan V, Subramaniapillai SG, Kuppuswamy AA, Mani A, Chittoor Neelakantan S, Nagarajan S.

Appl Microbiol Biotechnol. 2016 Nov;100(21):9265-9281. Epub 2016 Aug 16.

PMID:
27531512
16.

Bacterial multidrug efflux pumps: mechanisms, physiology and pharmacological exploitations.

Sun J, Deng Z, Yan A.

Biochem Biophys Res Commun. 2014 Oct 17;453(2):254-67. doi: 10.1016/j.bbrc.2014.05.090. Epub 2014 May 27. Review. Erratum in: Biochem Biophys Res Commun. 2015 Sep 11;465(1):165.

17.

Efflux pump inhibiting properties of racemic phenothiazine derivatives and their enantiomers on the bacterial AcrAB-TolC system.

Spengler G, Takács D, Horváth A, Szabó AM, Riedl Z, Hajós G, Molnár J, Burián K.

In Vivo. 2014 Nov-Dec;28(6):1071-5.

PMID:
25398801
18.

Inhibitors of bacterial multidrug efflux pumps potentiate antimicrobial photoinactivation.

Tegos GP, Masago K, Aziz F, Higginbotham A, Stermitz FR, Hamblin MR.

Antimicrob Agents Chemother. 2008 Sep;52(9):3202-9. doi: 10.1128/AAC.00006-08. Epub 2008 May 12.

19.

Involvement of efflux mechanisms in biocide resistance of Campylobacter jejuni and Campylobacter coli.

Mavri A, Mozina SS.

J Med Microbiol. 2012 Jun;61(Pt 6):800-8. doi: 10.1099/jmm.0.041467-0. Epub 2012 Feb 23.

PMID:
22361460
20.

Inhibitors of multidrug resistant efflux systems in bacteria.

Zechini B, Versace I.

Recent Pat Antiinfect Drug Discov. 2009 Jan;4(1):37-50. Review.

PMID:
19149695

Supplemental Content

Support Center